Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced that Russell H. Plumb, President and Chief Executive Officer, is scheduled to present an overview of the company and its pipeline of differentiated antiviral compounds at the following three investor conferences in November:

-- 2011 Credit Suisse Healthcare Conference on November 10, 2011 at 10:00 AM MST. The conference is being held at the Arizona Biltmore Resort Hotel & Spa in Phoenix, Arizona.

-- Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011 at 2:30 PM EST. The conference is being held at The Pierre Hotel in New York, NY. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at www.inhibitex.com. Shortly following the live webcast a replay will also be available on the Company website.

--23rd Annual Piper Jaffray Health Care Conference on November 30, 2011 at 1:00 PM EST. The conference is being held at The New York Palace hotel in New York, NY.

Mr. Plumb will also be attending the Brean Murray, Carret & Co. 2011 Life Sciences Summit on November 14, 2011. The conference is being held at the Grand Hyatt Hotel in New York, NY. There are no presentations at this conference.

About Inhibitex

Inhibitex, Inc. is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company's clinical-stage pipeline currently includes two Phase 2 development programs; INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections and FV-100, a nucleoside analogue in development for the treatment of shingles-associated pain. The Company also has other HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of a staphylococcal vaccine, which is currently being evaluated in a Phase 1/2 clinical trial.

For additional information about the Company, please visit www.inhibitex.com.

Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
rplumb@inhibitex.com
or
The Trout Group
Lee M. Stern, CFA, 646-378-2922
lstern@troutgroup.com